Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Balance Sheets

v3.25.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents [note 3 and note 7] $ 12,753 $ 15,546
Marketable securities [note 7] 21,607  
Grant receivable [note 4]   111
Prepaid expenses and other assets 2,107 1,325
Total current assets 36,467 16,982
Restricted cash and other assets [note 7 and note 8] 39 92
Right-of-use assets [note 12] 119 66
License agreement [note 5 and note 6] 974 1,197
Goodwill 1,034 1,034
Total assets 38,633 19,371
Current liabilities:    
Accounts payable 1,950 618
Accrued liabilities other 573 351
Accrued clinical liabilities 1,077 280
Accrued compensation 3,027 2,311
Contingent consideration [note 6 and note 7]   528
Current portion of long-term obligations [note 12] 55 63
Current portion of convertible debt [note 7 and note 9]   16,662
Total current liabilities 6,682 20,813
Non-current portion of convertible debt [note 7 and note 9] 9,837  
Contingent consideration [note 6 and note 7] 1,149  
Long-term obligations [note 12] 66 6
Total liabilities 17,734 20,819
Commitments and contingencies [note 12]
Stockholders' equity:    
Common stock, $0.001 par value, 150,000,000 shares authorized, 34,685,072 and 21,165,760 issued and outstanding at December 31, 2024 and December 31, 2023, respectively. 103 90
Additional paid-in capital 226,343 164,209
Accumulated deficit (205,578) (165,751)
Accumulated other comprehensive income 31 4
Total stockholders' equity 20,899 (1,448)
Total liabilities and stockholders' equity 38,633 19,371
Series A Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value